自体、异基因造血细胞移植及嵌合抗原受体T细胞/自然杀伤细胞疗法：它们在外周T细胞淋巴瘤中的实际重要性是什么？
Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL?
作者信息
Couto Samuel C F, Kowes Ariel, Aurabi Camila S, Oliveira Theo G M, Klinger Paulo, Rocha Vanderson
机构信息
Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology and Cell Therapy, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil.
Fundação Pró-Sangue-Hemocentro de São Paulo, São Paulo, Brazil.
出版信息
Front Oncol. 2023 Aug 30;13:1195759. doi: 10.3389/fonc.2023.1195759. eCollection 2023.
Peripheral T cell lymphoma (PTCL) is a rare and aggressive type of non-Hodgkin's lymphoma that affects mature T cells. This type of cancer is characterized by the abnormal growth of T cells, which can accumulate in the lymph nodes, spleen, bone marrow, and other organs, leading to a variety of symptoms. PTCLs are often difficult to diagnose and treat, and they have a poorer prognosis than other types of lymphoma. However, recent advancements in treatment options, such as targeted therapies have shown promise in improving outcomes for patients with PTCL. Here, we discuss the use of autologous and allogeneic hematopoietic cell transplantation (HCT) as a treatment strategy for patients with PTCL, as well as the recent treatment approaches based on advanced cellular therapy. The current evidence for the use of HCT in PTCL is mainly derived from registry data, retrospective studies, and expert opinion, as randomized trials are limited due to the low incidence and histological heterogeneity of PTCL subtypes.
外周T细胞淋巴瘤（PTCL）是一种罕见且侵袭性强的非霍奇金淋巴瘤，影响成熟T细胞。这种癌症的特征是T细胞异常生长，可积聚在淋巴结、脾脏、骨髓和其他器官中，导致各种症状。PTCL通常难以诊断和治疗，其预后比其他类型的淋巴瘤更差。然而，最近治疗方案的进展，如靶向治疗，已显示出有望改善PTCL患者的治疗效果。在此，我们讨论自体和异基因造血细胞移植（HCT）作为PTCL患者的治疗策略，以及基于先进细胞疗法的最新治疗方法。目前关于在PTCL中使用HCT的证据主要来自登记数据、回顾性研究和专家意见，因为由于PTCL亚型的发病率低和组织学异质性，随机试验有限。
Zotero 插件